866-997-4948(US-Canada Toll Free)

Metastatic Prostate Cancer - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Cancer

No. of Pages : 106 Pages


Metastatic Prostate Cancer Pipeline Review, H2 2012

Global Markets Directs, \'Metastatic Prostate Cancer Pipeline Review, H2 2012\', provides an overview of the Metastatic Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer. \'Metastatic Prostate Cancer Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Prostate Cancer.
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Metastatic Prostate Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Prostate Cancer Therapeutic Products under Development, Key Players in Metastatic Prostate Cancer Therapeutics, Metastatic Prostate Cancer Pipeline Overview, Metastatic Prostate Cancer Pipeline, Metastatic Prostate Cancer Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Prostate Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Metastatic Prostate Cancer 11
Metastatic Prostate Cancer Therapeutics under Development by Companies 13
Metastatic Prostate Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Metastatic Prostate Cancer Therapeutics Products under Development by Companies 21
Metastatic Prostate Cancer Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Metastatic Prostate Cancer Therapeutics Development 23
Sanofi-Aventis 23
AstraZeneca PLC 24
Bavarian Nordic A/S 25
Merck KGaA 26
Oncothyreon Inc 27
Osta Biotechnologies Inc. 28
Medivation, Inc. 29
Regeneron Pharmaceuticals, Inc. 30
Actinium Pharmaceuticals, Inc. 31
S*BIO Pte Ltd 32
NewLink Genetics Corporation 33
Bellicum Pharmaceuticals, Inc. 34
Metastatic Prostate Cancer Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 42
DI17E6 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Enzalutamide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SB-939 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PX-866 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Zometa + Taxotere - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BMTP-11 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Docetaxel + RAD001 + Avastin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Zactima + Casodex - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Gemcitabine + Docetaxel - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Zoledronic Acid - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Capecitabine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Aflibercept + Docetaxel + Prednisone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Taxol - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Samarium-153 EDTMP - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Vorinostat + Temsirolimus - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Vinorelbine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Jevtana - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AntiAndrogen Therapy + Goserelin + Docetaxel - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Samarium Sm 153 Lexidronam Pentasodium + Sargramostim + Recombinant Vaccinia-TRICOM Vaccine + Recombinant fowlpox-TRICOM - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 69
Bicalutamide + Goserelin Acetate + Leuprolide Acetate + IMC-A12 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
CCI-779 + IMC-A12 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
OB-24 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Zaltrap - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Docetaxel + Gemcitabine + Prednisone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NLG8189 + Taxotere - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BPX-101 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Vaccine For Metastatic Prostate Cancer - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Actimab-P - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
XRP6258 + Abiraterone + Prednisone - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Prostvac + Ipilimumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Anti-OX40 Monoclonal Antibody + Cyclophosphamide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Metastatic Prostate Cancer Therapeutics Drug Profile Updates 89
Metastatic Prostate Cancer Therapeutics Discontinued Products 99
Metastatic Prostate Cancer Therapeutics - Dormant Products 100
Metastatic Prostate Cancer Product Development Milestones 102
Featured News & Press Releases 102
Jun 27, 2012: Astellas Pharma And Medivation Announce European Regulatory Submission For Enzalutamide For Treatment Of Prostate Cancer 102
Jun 02, 2012: Zytiga\'s Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 102
May 16, 2012: J&J\'s ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 103
Feb 24, 2012: Active Biotech And Ipsen Report Tasquinimod Phase II Long Term Safety Data At 27th European Association Of Urology Congress 103

Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Table


Number of Products Under Development for Metastatic Prostate Cancer, H2 2012 11
Products under Development for Metastatic Prostate Cancer Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Sanofi-Aventis, H2 2012 23
AstraZeneca PLC, H2 2012 24
Bavarian Nordic A/S, H2 2012 25
Merck KGaA, H2 2012 26
Oncothyreon Inc, H2 2012 27
Osta Biotechnologies Inc., H2 2012 28
Medivation, Inc., H2 2012 29
Regeneron Pharmaceuticals, Inc., H2 2012 30
Actinium Pharmaceuticals, Inc., H2 2012 31
S*BIO Pte Ltd, H2 2012 32
NewLink Genetics Corporation, H2 2012 33
Bellicum Pharmaceuticals, Inc., H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 41
Metastatic Prostate Cancer Therapeutics Drug Profile Updates 89
Metastatic Prostate Cancer Therapeutics Discontinued Products 99
Metastatic Prostate Cancer Therapeutics Dormant Products 100
Metastatic Prostate Cancer Therapeutics Dormant Products (Contd..1) 101

List of Chart


Number of Products under Development for Metastatic Prostate Cancer, H2 2012 11
Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Route of Administration, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Molecule Type, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *